Skip to main content
Top
Published in: AIDS and Behavior 9/2023

16-03-2023 | Human Immunodeficiency Virus | Original Paper

Injection Drug Use and Sexual Risk Behaviors Among People who Inject Drugs in Ukraine: A Random-Intercept Latent Transition Analysis

Authors: John Mark Wiginton, Robert Booth, Lisa A. Eaton, Laramie R. Smith, Cristina Espinosa da Silva, Thomas L. Patterson, Eileen V. Pitpitan

Published in: AIDS and Behavior | Issue 9/2023

Login to get access

Abstract

HIV transmission in Ukraine is driven in part by unsafe injection drug use and sexual risk behaviors among people who inject drugs. We performed a random-intercept latent transition analysis on responses to 9 binary injection drug use and sexual behavior items from 1195 people who inject drugs with negative HIV status enrolled in a clustered randomized clinical trial of a social network intervention in Odessa, Donetsk, and Nikolayev, Ukraine. We identified 5 baseline classes: “Social injection/equipment-sharing” (11.7%), “Social injection” (25.9%), “High-risk collective preparation/splitting” (17.0%), “Collective preparation/splitting” (11.3%), and “Dealer-facilitated injection” (34.1%). After 12 months, intervention participants were more likely to transition to the “Collective preparation/splitting” class, which featured the fewest risk behaviors. Transitioning from the “Collective preparation/splitting” to the “Social injection/equipment-sharing” class was associated with HIV acquisition for control participants. Research to illuminate the stability of these patterns and how they may benefit from uniquely tailored programming to reduce unsafe behaviors is needed.
Literature
1.
go back to reference Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192–207.PubMedCrossRef Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192–207.PubMedCrossRef
2.
go back to reference Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376(9737):285–301.PubMedCrossRef Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376(9737):285–301.PubMedCrossRef
3.
go back to reference De P, Cox J, Boivin JF, Platt RW, Jolly AM. The importance of social networks in their association to drug equipment sharing among injection drug users: a review. Addiction. 2007;102(11):1730–9.PubMedCrossRef De P, Cox J, Boivin JF, Platt RW, Jolly AM. The importance of social networks in their association to drug equipment sharing among injection drug users: a review. Addiction. 2007;102(11):1730–9.PubMedCrossRef
4.
go back to reference Degenhardt L, Charlson F, Stanaway J, Larney S, Alexander LT, Hickman M, et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016;16(12):1385–98.PubMedCrossRef Degenhardt L, Charlson F, Stanaway J, Larney S, Alexander LT, Hickman M, et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016;16(12):1385–98.PubMedCrossRef
5.
go back to reference Des Jarlais DC, Feelemyer JP, Modi SN, Arasteh K, Mathers BM, Degenhardt L, et al. Transitions from injection-drug-use-concentrated to self-sustaining heterosexual HIV epidemics: patterns in the international data. PLoS ONE. 2012;7(3): e31227.PubMedPubMedCentralCrossRef Des Jarlais DC, Feelemyer JP, Modi SN, Arasteh K, Mathers BM, Degenhardt L, et al. Transitions from injection-drug-use-concentrated to self-sustaining heterosexual HIV epidemics: patterns in the international data. PLoS ONE. 2012;7(3): e31227.PubMedPubMedCentralCrossRef
6.
go back to reference Rachlis B, Brouwer KC, Mills EJ, Hayes M, Kerr T, Hogg RS. Migration and transmission of blood-borne infections among injection drug users: understanding the epidemiologic bridge. Drug Alcohol Depend. 2007;90(2–3):107–19.PubMedCrossRef Rachlis B, Brouwer KC, Mills EJ, Hayes M, Kerr T, Hogg RS. Migration and transmission of blood-borne infections among injection drug users: understanding the epidemiologic bridge. Drug Alcohol Depend. 2007;90(2–3):107–19.PubMedCrossRef
11.
go back to reference Burruano L, Kruglov Y. HIV/AIDS epidemic in Eastern Europe: recent developments in the Russian Federation and Ukraine among women. Gend Med. 2009;6(1):277–89.PubMedCrossRef Burruano L, Kruglov Y. HIV/AIDS epidemic in Eastern Europe: recent developments in the Russian Federation and Ukraine among women. Gend Med. 2009;6(1):277–89.PubMedCrossRef
12.
go back to reference Vitek CR, Čakalo JI, Kruglov YV, Dumchev KV, Salyuk TO, Božičević I, et al. Slowing of the HIV epidemic in Ukraine: evidence from case reporting and key population surveys, 2005–2012. PLoS ONE. 2014;9(9): e103657.PubMedPubMedCentralCrossRef Vitek CR, Čakalo JI, Kruglov YV, Dumchev KV, Salyuk TO, Božičević I, et al. Slowing of the HIV epidemic in Ukraine: evidence from case reporting and key population surveys, 2005–2012. PLoS ONE. 2014;9(9): e103657.PubMedPubMedCentralCrossRef
13.
go back to reference Latkin CA. Outreach in natural settings: the use of peer leaders for HIV prevention among injecting drug users’ networks. Public Health Rep. 1998;113(Suppl 1):151–9.PubMedPubMedCentral Latkin CA. Outreach in natural settings: the use of peer leaders for HIV prevention among injecting drug users’ networks. Public Health Rep. 1998;113(Suppl 1):151–9.PubMedPubMedCentral
14.
go back to reference Theall KP, Sterk CE, Elifson KW, Kidder D. Factors associated with positive HIV serostatus among women who use drugs: continued evidence for expanding factors of influence. Public Health Rep. 2003;118(5):415–24.PubMedPubMedCentralCrossRef Theall KP, Sterk CE, Elifson KW, Kidder D. Factors associated with positive HIV serostatus among women who use drugs: continued evidence for expanding factors of influence. Public Health Rep. 2003;118(5):415–24.PubMedPubMedCentralCrossRef
15.
go back to reference Tobin KE, Kuramoto SJ, Davey-Rothwell MA, Latkin CA. The STEP into Action study: a peer-based, personal risk network-focused HIV prevention intervention with injection drug users in Baltimore, Maryland. Addiction. 2011;106(2):366–75.PubMedCrossRef Tobin KE, Kuramoto SJ, Davey-Rothwell MA, Latkin CA. The STEP into Action study: a peer-based, personal risk network-focused HIV prevention intervention with injection drug users in Baltimore, Maryland. Addiction. 2011;106(2):366–75.PubMedCrossRef
16.
go back to reference Neaigus A, Gyarmathy VA, Miller M, Frajzyngier VM, Friedman SR, Des Jarlais DC. Transitions to injecting drug use among noninjecting heroin users: social network influence and individual susceptibility. J Acquir Immune Defic Syndr. 2006;41(4):493–503.PubMedCrossRef Neaigus A, Gyarmathy VA, Miller M, Frajzyngier VM, Friedman SR, Des Jarlais DC. Transitions to injecting drug use among noninjecting heroin users: social network influence and individual susceptibility. J Acquir Immune Defic Syndr. 2006;41(4):493–503.PubMedCrossRef
17.
go back to reference Ghosh D, Krishnan A, Gibson B, Brown SE, Latkin CA, Altice FL. Social network strategies to address HIV prevention and treatment continuum of care among at-risk and HIV-infected substance users: a systematic scoping review. AIDS Behav. 2017;21(4):1183–207.PubMedPubMedCentralCrossRef Ghosh D, Krishnan A, Gibson B, Brown SE, Latkin CA, Altice FL. Social network strategies to address HIV prevention and treatment continuum of care among at-risk and HIV-infected substance users: a systematic scoping review. AIDS Behav. 2017;21(4):1183–207.PubMedPubMedCentralCrossRef
18.
go back to reference Booth RE, Lehman WE, Latkin CA, Dvoryak S, Brewster JT, Royer MS, et al. Individual and network interventions with injection drug users in 5 Ukraine cities. Am J Public Health. 2011;101(2):336–43.PubMedPubMedCentralCrossRef Booth RE, Lehman WE, Latkin CA, Dvoryak S, Brewster JT, Royer MS, et al. Individual and network interventions with injection drug users in 5 Ukraine cities. Am J Public Health. 2011;101(2):336–43.PubMedPubMedCentralCrossRef
19.
go back to reference Booth RE, Lehman WEK, Latkin CA, Brewster JT, Sinitsyna L, Dvoryak S. Use of a peer leader intervention model to reduce needle-related risk behaviors among drug injectors in Ukraine. J Drug Iss. 2009;39(3):607–25.CrossRef Booth RE, Lehman WEK, Latkin CA, Brewster JT, Sinitsyna L, Dvoryak S. Use of a peer leader intervention model to reduce needle-related risk behaviors among drug injectors in Ukraine. J Drug Iss. 2009;39(3):607–25.CrossRef
20.
go back to reference Latkin CA, Donnell D, Metzger D, Sherman S, Aramrattna A, Davis-Vogel A, et al. The efficacy of a network intervention to reduce HIV risk behaviors among drug users and risk partners in Chiang Mai, Thailand and Philadelphia, USA. Soc Sci Med. 2009;68(4):740–8.PubMedCrossRef Latkin CA, Donnell D, Metzger D, Sherman S, Aramrattna A, Davis-Vogel A, et al. The efficacy of a network intervention to reduce HIV risk behaviors among drug users and risk partners in Chiang Mai, Thailand and Philadelphia, USA. Soc Sci Med. 2009;68(4):740–8.PubMedCrossRef
21.
go back to reference Latkin CA, Sherman S, Knowlton A. HIV prevention among drug users: outcome of a network-oriented peer outreach intervention. Health Psychol. 2003;22(4):332–9.PubMedCrossRef Latkin CA, Sherman S, Knowlton A. HIV prevention among drug users: outcome of a network-oriented peer outreach intervention. Health Psychol. 2003;22(4):332–9.PubMedCrossRef
22.
go back to reference Hoffman IF, Latkin CA, Kukhareva PV, Malov SV, Batluk JV, Shaboltas AV, et al. A peer-educator network HIV prevention intervention among injection drug users: results of a randomized controlled trial in St. Petersburg, Russia. AIDS Behav. 2013;17(7):2510–20.PubMedPubMedCentralCrossRef Hoffman IF, Latkin CA, Kukhareva PV, Malov SV, Batluk JV, Shaboltas AV, et al. A peer-educator network HIV prevention intervention among injection drug users: results of a randomized controlled trial in St. Petersburg, Russia. AIDS Behav. 2013;17(7):2510–20.PubMedPubMedCentralCrossRef
23.
go back to reference Mihailovic A, Tobin K, Latkin C. The influence of a peer-based HIV prevention intervention on conversation about HIV prevention among people who inject drugs in Baltimore, Maryland. AIDS Behav. 2015;19(10):1792–800.PubMedPubMedCentralCrossRef Mihailovic A, Tobin K, Latkin C. The influence of a peer-based HIV prevention intervention on conversation about HIV prevention among people who inject drugs in Baltimore, Maryland. AIDS Behav. 2015;19(10):1792–800.PubMedPubMedCentralCrossRef
24.
go back to reference Booth RE, Davis JM, Dvoryak S, Brewster JT, Lisovska O, Strathdee SA, et al. HIV incidence among people who inject drugs (PWIDs) in Ukraine: results from a clustered randomised trial. Lancet HIV. 2016;3(10):e482–9.PubMedPubMedCentralCrossRef Booth RE, Davis JM, Dvoryak S, Brewster JT, Lisovska O, Strathdee SA, et al. HIV incidence among people who inject drugs (PWIDs) in Ukraine: results from a clustered randomised trial. Lancet HIV. 2016;3(10):e482–9.PubMedPubMedCentralCrossRef
25.
go back to reference Mackesy-Amiti ME, Finnegan L, Ouellet LJ, Golub ET, Hagan H, Hudson SM, et al. Peer-education intervention to reduce injection risk behaviors benefits high-risk young injection drug users: a latent transition analysis of the CIDUS 3/DUIT study. AIDS Behav. 2013;17(6):2075–83.PubMedCrossRef Mackesy-Amiti ME, Finnegan L, Ouellet LJ, Golub ET, Hagan H, Hudson SM, et al. Peer-education intervention to reduce injection risk behaviors benefits high-risk young injection drug users: a latent transition analysis of the CIDUS 3/DUIT study. AIDS Behav. 2013;17(6):2075–83.PubMedCrossRef
26.
go back to reference Sharifi H, Mirzazadeh A, Noroozi A, Marshall BD, Farhoudian A, Higgs P, et al. Patterns of HIV risks and related factors among people who inject drugs in Kermanshah, Iran: a latent class analysis. J Psychoactive Drugs. 2017;49(1):69–73.PubMedCrossRef Sharifi H, Mirzazadeh A, Noroozi A, Marshall BD, Farhoudian A, Higgs P, et al. Patterns of HIV risks and related factors among people who inject drugs in Kermanshah, Iran: a latent class analysis. J Psychoactive Drugs. 2017;49(1):69–73.PubMedCrossRef
27.
go back to reference Noor SW, Ross MW, Lai D, Risser JM. Use of latent class analysis approach to describe drug and sexual HIV risk patterns among injection drug users in Houston, Texas. AIDS Behav. 2014;18(Suppl 3):276–83.PubMedCrossRef Noor SW, Ross MW, Lai D, Risser JM. Use of latent class analysis approach to describe drug and sexual HIV risk patterns among injection drug users in Houston, Texas. AIDS Behav. 2014;18(Suppl 3):276–83.PubMedCrossRef
28.
go back to reference Nylund-Gibson K, Choi AY. Ten frequently asked questions about latent class analysis. Trans Issues Psychol Sci. 2018;4(4):440–61.CrossRef Nylund-Gibson K, Choi AY. Ten frequently asked questions about latent class analysis. Trans Issues Psychol Sci. 2018;4(4):440–61.CrossRef
29.
go back to reference Lanza ST, Patrick ME, Maggs JL. Latent transition analysis: benefits of a latent variable approach to modeling transitions in substance use. J Drug Issues. 2010;40(1):93–120.PubMedPubMedCentralCrossRef Lanza ST, Patrick ME, Maggs JL. Latent transition analysis: benefits of a latent variable approach to modeling transitions in substance use. J Drug Issues. 2010;40(1):93–120.PubMedPubMedCentralCrossRef
31.
go back to reference Latkin CA, Forman V, Knowlton A, Sherman S. Norms, social networks, and HIV-related risk behaviors among urban disadvantaged drug users. Soc Sci Med. 2003;56(3):465–76.PubMedCrossRef Latkin CA, Forman V, Knowlton A, Sherman S. Norms, social networks, and HIV-related risk behaviors among urban disadvantaged drug users. Soc Sci Med. 2003;56(3):465–76.PubMedCrossRef
32.
go back to reference Latkin CA, Hua W, Davey MA. Factors associated with peer HIV prevention outreach in drug-using communities. AIDS Educ Prev. 2004;16(6):499–508.PubMedCrossRef Latkin CA, Hua W, Davey MA. Factors associated with peer HIV prevention outreach in drug-using communities. AIDS Educ Prev. 2004;16(6):499–508.PubMedCrossRef
34.
go back to reference Muthén B, Asparouhov T. Latent transition analysis with random intercepts (RI-LTA). Psychol Methods 2020 11/23. Muthén B, Asparouhov T. Latent transition analysis with random intercepts (RI-LTA). Psychol Methods 2020 11/23.
35.
go back to reference Collins LM, Schafer JL, Kam CM. A comparison of inclusive and restrictive strategies in modern missing data procedures. Psychol Methods. 2001;6(4):330–51.PubMedCrossRef Collins LM, Schafer JL, Kam CM. A comparison of inclusive and restrictive strategies in modern missing data procedures. Psychol Methods. 2001;6(4):330–51.PubMedCrossRef
36.
go back to reference Schafer JL, Graham JW. Missing data: our view of the state of the art. Psychol Methods. 2002;7(2):147–77.PubMedCrossRef Schafer JL, Graham JW. Missing data: our view of the state of the art. Psychol Methods. 2002;7(2):147–77.PubMedCrossRef
38.
go back to reference StatCorp LLC. Stata statistical software, release 15. 2017. College Station, TX: StataCorp LLC. StatCorp LLC. Stata statistical software, release 15. 2017. College Station, TX: StataCorp LLC.
39.
go back to reference Muthen B, Muthen L. Mplus User's Guide (8th ed.). 1998–2018;8. Los Angeles, CA: Muthen & Muthen. Muthen B, Muthen L. Mplus User's Guide (8th ed.). 1998–2018;8. Los Angeles, CA: Muthen & Muthen.
40.
go back to reference Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimating per-act HIV transmission risk: a systematic review. AIDS. 2014;28(10):1509–19.PubMedCrossRef Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimating per-act HIV transmission risk: a systematic review. AIDS. 2014;28(10):1509–19.PubMedCrossRef
41.
go back to reference Booth RE, Kennedy J, Brewster T, Semerik O. Drug injectors and dealers in Odessa, Ukraine. J Psychoactive Drugs. 2003;35(4):419–26.PubMedCrossRef Booth RE, Kennedy J, Brewster T, Semerik O. Drug injectors and dealers in Odessa, Ukraine. J Psychoactive Drugs. 2003;35(4):419–26.PubMedCrossRef
42.
go back to reference Booth RE, Kwiatkowski CF, Brewster JT, Sinitsyna L, Dvoryak S. Predictors of HIV sero-status among drug injectors at three Ukraine sites. AIDS. 2006;20(17):2217–23.PubMedCrossRef Booth RE, Kwiatkowski CF, Brewster JT, Sinitsyna L, Dvoryak S. Predictors of HIV sero-status among drug injectors at three Ukraine sites. AIDS. 2006;20(17):2217–23.PubMedCrossRef
43.
go back to reference Makarenko I, Ompad DC, Sazonova Y, Saliuk T, DeHovitz J, Gensburg L. Trends in injection risk behaviors among people who inject drugs and the impact of harm reduction programs in Ukraine, 2007–2013. J Urban Health. 2017;94(1):104–14.PubMedPubMedCentralCrossRef Makarenko I, Ompad DC, Sazonova Y, Saliuk T, DeHovitz J, Gensburg L. Trends in injection risk behaviors among people who inject drugs and the impact of harm reduction programs in Ukraine, 2007–2013. J Urban Health. 2017;94(1):104–14.PubMedPubMedCentralCrossRef
44.
go back to reference Mazhnaya A, Kiriazova T, Chernova O, Tobin K, Owczarzak J. “Now it is mostly done through stashes, to do it in person one has to trust you”: Understanding the retail injection drug market in Dnipro. Ukraine Int J Drug Policy. 2021;87: 102988.PubMedCrossRef Mazhnaya A, Kiriazova T, Chernova O, Tobin K, Owczarzak J. “Now it is mostly done through stashes, to do it in person one has to trust you”: Understanding the retail injection drug market in Dnipro. Ukraine Int J Drug Policy. 2021;87: 102988.PubMedCrossRef
45.
go back to reference Dejong W, Wolf RC, Austin SB. U.S. Federally funded television public service announcements (PSAs) to prevent HIV/AIDS: a content analysis. J Health Commun. 2001;6(3):249–63.PubMedCrossRef Dejong W, Wolf RC, Austin SB. U.S. Federally funded television public service announcements (PSAs) to prevent HIV/AIDS: a content analysis. J Health Commun. 2001;6(3):249–63.PubMedCrossRef
46.
go back to reference Sinding SW. Does “CNN” (condoms, needles and negotiation) work better than “ABC” (abstinence, being faithful and condom use) in attacking the AIDS epidemic? Int Fam Plan Perspect. 2005;31(1):38–40.PubMedCrossRef Sinding SW. Does “CNN” (condoms, needles and negotiation) work better than “ABC” (abstinence, being faithful and condom use) in attacking the AIDS epidemic? Int Fam Plan Perspect. 2005;31(1):38–40.PubMedCrossRef
47.
48.
49.
go back to reference Bryant J, Brener L, Hull P, Treloar C. Needle sharing in regular sexual relationships: an examination of serodiscordance, drug using practices, and the gendered character of injecting. Drug Alcohol Depend. 2010;107(2–3):182–7.PubMedCrossRef Bryant J, Brener L, Hull P, Treloar C. Needle sharing in regular sexual relationships: an examination of serodiscordance, drug using practices, and the gendered character of injecting. Drug Alcohol Depend. 2010;107(2–3):182–7.PubMedCrossRef
50.
go back to reference Rance J, Rhodes T, Fraser S, Bryant J, Treloar C. Practices of partnership: negotiated safety among couples who inject drugs. Health (London). 2018;22(1):3–19.PubMedCrossRef Rance J, Rhodes T, Fraser S, Bryant J, Treloar C. Practices of partnership: negotiated safety among couples who inject drugs. Health (London). 2018;22(1):3–19.PubMedCrossRef
51.
go back to reference Deryabina AP, Patnaik P, El-Sadr WM. Underreported injection drug use and its potential contribution to reported increase in sexual transmission of HIV in Kazakhstan and Kyrgyzstan. Harm Reduct J. 2019;16(1):1-018-0274–2.CrossRef Deryabina AP, Patnaik P, El-Sadr WM. Underreported injection drug use and its potential contribution to reported increase in sexual transmission of HIV in Kazakhstan and Kyrgyzstan. Harm Reduct J. 2019;16(1):1-018-0274–2.CrossRef
52.
go back to reference Davlidova S, Haley-Johnson Z, Nyhan K, Farooq A, Vermund SH, Ali S. Prevalence of HIV, HCV and HBV in Central Asia and the Caucasus: a systematic review. Int J Infect Dis. 2021;104:510–25.PubMedCrossRef Davlidova S, Haley-Johnson Z, Nyhan K, Farooq A, Vermund SH, Ali S. Prevalence of HIV, HCV and HBV in Central Asia and the Caucasus: a systematic review. Int J Infect Dis. 2021;104:510–25.PubMedCrossRef
54.
go back to reference Uusküla A, Raag M, Folch C, Prasad L, Karnite A, van Veen MG, et al. Self-reported testing, HIV status and associated risk behaviours among people who inject drugs in Europe: important differences between East and West. AIDS. 2014;28(11):1657–64.PubMedCrossRef Uusküla A, Raag M, Folch C, Prasad L, Karnite A, van Veen MG, et al. Self-reported testing, HIV status and associated risk behaviours among people who inject drugs in Europe: important differences between East and West. AIDS. 2014;28(11):1657–64.PubMedCrossRef
55.
go back to reference Tran LT, Peacock A, Colledge S, Memedovic S, Grebely J, Leung J, et al. Injecting risk behaviours amongst people who inject drugs: a global multi-stage systematic review and meta-analysis. Int J Drug Policy. 2020;84: 102866.PubMedCrossRef Tran LT, Peacock A, Colledge S, Memedovic S, Grebely J, Leung J, et al. Injecting risk behaviours amongst people who inject drugs: a global multi-stage systematic review and meta-analysis. Int J Drug Policy. 2020;84: 102866.PubMedCrossRef
56.
go back to reference Otiashvili D, Latypov A, Kirtadze I, Ibragimov U, Zule W. Drug preparation, injection, and sharing practices in Tajikistan: a qualitative study in Kulob and Khorog. Subst Abuse Treat Prev Policy. 2016;11(1):21.PubMedPubMedCentralCrossRef Otiashvili D, Latypov A, Kirtadze I, Ibragimov U, Zule W. Drug preparation, injection, and sharing practices in Tajikistan: a qualitative study in Kulob and Khorog. Subst Abuse Treat Prev Policy. 2016;11(1):21.PubMedPubMedCentralCrossRef
57.
go back to reference Dumchev KV, Soldyshev R, Qian HZ, Zezyulin OO, Chandler SD, Slobodyanyuk P, et al. HIV and hepatitis C virus infections among hanka injection drug users in central Ukraine: a cross-sectional survey. Harm Reduct J. 2009;23(6):23-7517-6–23. Dumchev KV, Soldyshev R, Qian HZ, Zezyulin OO, Chandler SD, Slobodyanyuk P, et al. HIV and hepatitis C virus infections among hanka injection drug users in central Ukraine: a cross-sectional survey. Harm Reduct J. 2009;23(6):23-7517-6–23.
58.
go back to reference Kruse GR, Barbour R, Heimer R, Shaboltas AV, Toussova OV, Hoffman IF, et al. Drug choice, spatial distribution, HIV risk, and HIV prevalence among injection drug users in St. Petersburg, Russia. Harm Reduct J. 2009;6:22-7517-6–22.CrossRef Kruse GR, Barbour R, Heimer R, Shaboltas AV, Toussova OV, Hoffman IF, et al. Drug choice, spatial distribution, HIV risk, and HIV prevalence among injection drug users in St. Petersburg, Russia. Harm Reduct J. 2009;6:22-7517-6–22.CrossRef
59.
go back to reference Sazonova Y, Kulchynska R, Sereda Y, Azarskova M, Novak Y, Saliuk T, et al. HIV treatment cascade among people who inject drugs in Ukraine. PLoS ONE. 2020;15(12): e0244572.PubMedPubMedCentralCrossRef Sazonova Y, Kulchynska R, Sereda Y, Azarskova M, Novak Y, Saliuk T, et al. HIV treatment cascade among people who inject drugs in Ukraine. PLoS ONE. 2020;15(12): e0244572.PubMedPubMedCentralCrossRef
60.
go back to reference Bojko MJ, Mazhnaya A, Makarenko I, Marcus R, Dvoriak S, Islam Z, et al. “Bureaucracy & beliefs”: assessing the barriers to accessing opioid substitution therapy by people who inject drugs in Ukraine. Drugs (Abingdon Engl). 2015;22(3):255–62.PubMed Bojko MJ, Mazhnaya A, Makarenko I, Marcus R, Dvoriak S, Islam Z, et al. “Bureaucracy & beliefs”: assessing the barriers to accessing opioid substitution therapy by people who inject drugs in Ukraine. Drugs (Abingdon Engl). 2015;22(3):255–62.PubMed
61.
go back to reference Lee JO, Yoon Y, Idrisov B, Kiriazova T, Makarenko O, Sereda Y, et al. Violence, HIV risks, and polysubstance use among HIV-positive people who inject drugs in Ukraine. AIDS Behav. 2021;25(7):2120–30.PubMedPubMedCentralCrossRef Lee JO, Yoon Y, Idrisov B, Kiriazova T, Makarenko O, Sereda Y, et al. Violence, HIV risks, and polysubstance use among HIV-positive people who inject drugs in Ukraine. AIDS Behav. 2021;25(7):2120–30.PubMedPubMedCentralCrossRef
62.
go back to reference Corsi KF, Dvoryak S, Garver-Apgar C, Davis JM, Brewster JT, Lisovska O, et al. Gender differences between predictors of HIV status among PWID in Ukraine. Drug Alcohol Depend. 2014;1(138):103–8.CrossRef Corsi KF, Dvoryak S, Garver-Apgar C, Davis JM, Brewster JT, Lisovska O, et al. Gender differences between predictors of HIV status among PWID in Ukraine. Drug Alcohol Depend. 2014;1(138):103–8.CrossRef
63.
go back to reference Mazhnaya A, Tobin KE, Owczarzak J. Association between injection in public places and HIV/HCV risk behavior among people who use drugs in Ukraine. Drug Alcohol Depend. 2018;1(189):125–30.CrossRef Mazhnaya A, Tobin KE, Owczarzak J. Association between injection in public places and HIV/HCV risk behavior among people who use drugs in Ukraine. Drug Alcohol Depend. 2018;1(189):125–30.CrossRef
64.
go back to reference Owczarzak J, Nguyen TQ, Mazhnaya A, Phillips SD, Filippova O, Alpatova P, et al. Outcome evaluation of a “common factors” approach to develop culturally tailored HIV prevention interventions for people who inject drugs. Drug Alcohol Depend. 2019;1(199):18–26.CrossRef Owczarzak J, Nguyen TQ, Mazhnaya A, Phillips SD, Filippova O, Alpatova P, et al. Outcome evaluation of a “common factors” approach to develop culturally tailored HIV prevention interventions for people who inject drugs. Drug Alcohol Depend. 2019;1(199):18–26.CrossRef
65.
go back to reference Kuzin I, Martzynovska V, Antonenko Z. HIV infection in Ukraine. Public Health Center of the Ministry of Health of Ukraine. 2020; Newsletter No. 51. Kuzin I, Martzynovska V, Antonenko Z. HIV infection in Ukraine. Public Health Center of the Ministry of Health of Ukraine. 2020; Newsletter No. 51.
67.
go back to reference Meteliuk A, Galvez de Leon, Samy J, Madden LM, Pykalo I, Fomenko T, Filippovych M, et al. Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine. J Subst Abuse Treat. 2021;121:108164.PubMedCrossRef Meteliuk A, Galvez de Leon, Samy J, Madden LM, Pykalo I, Fomenko T, Filippovych M, et al. Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine. J Subst Abuse Treat. 2021;121:108164.PubMedCrossRef
69.
go back to reference Essar MY, Matiashova L, Tsagkaris C, Vladychuk V, Head M. Infectious diseases amidst a humanitarian crisis in Ukraine: a rising concern. Ann Med Surg (Lond). 2022;3(78): 103950. Essar MY, Matiashova L, Tsagkaris C, Vladychuk V, Head M. Infectious diseases amidst a humanitarian crisis in Ukraine: a rising concern. Ann Med Surg (Lond). 2022;3(78): 103950.
70.
go back to reference Vasylyeva TI, Smyrnov P, Strathdee S, Friedman SR. Challenges posed by COVID-19 to people who inject drugs and lessons from other outbreaks. J Int AIDS Soc. 2020;23(7): e25583.PubMedPubMedCentralCrossRef Vasylyeva TI, Smyrnov P, Strathdee S, Friedman SR. Challenges posed by COVID-19 to people who inject drugs and lessons from other outbreaks. J Int AIDS Soc. 2020;23(7): e25583.PubMedPubMedCentralCrossRef
71.
go back to reference Filippovych S. Impact of armed conflicts and warfare on opioid substitution treatment in Ukraine: responding to emergency needs. Int J Drug Policy. 2015;26(1):3–5.PubMedCrossRef Filippovych S. Impact of armed conflicts and warfare on opioid substitution treatment in Ukraine: responding to emergency needs. Int J Drug Policy. 2015;26(1):3–5.PubMedCrossRef
72.
go back to reference Kazatchkine M. Russia’s ban on methadone for drug users in Crimea will worsen the HIV/AIDS epidemic and risk public health. BMJ. 2014;8(348): g3118.CrossRef Kazatchkine M. Russia’s ban on methadone for drug users in Crimea will worsen the HIV/AIDS epidemic and risk public health. BMJ. 2014;8(348): g3118.CrossRef
73.
go back to reference Vasylyeva TI, Liulchuk M, Friedman SR, Sazonova I, Faria NR, Katzourakis A, et al. Molecular epidemiology reveals the role of war in the spread of HIV in Ukraine. Proc Natl Acad Sci USA. 2018;115(5):1051–6.PubMedPubMedCentralCrossRef Vasylyeva TI, Liulchuk M, Friedman SR, Sazonova I, Faria NR, Katzourakis A, et al. Molecular epidemiology reveals the role of war in the spread of HIV in Ukraine. Proc Natl Acad Sci USA. 2018;115(5):1051–6.PubMedPubMedCentralCrossRef
74.
go back to reference Altice FL, Bromberg DJ, Dvoriak S, Meteliuk A, Pykalo I, Islam Z, et al. Extending a lifeline to people with HIV and opioid use disorder during the war in Ukraine. Lancet Public Health. 2022;7(5):e482–4.PubMedPubMedCentralCrossRef Altice FL, Bromberg DJ, Dvoriak S, Meteliuk A, Pykalo I, Islam Z, et al. Extending a lifeline to people with HIV and opioid use disorder during the war in Ukraine. Lancet Public Health. 2022;7(5):e482–4.PubMedPubMedCentralCrossRef
75.
go back to reference Kai J, Parczewski M, van de Vijver D. The war refugees from Ukraine: an HIV epidemic is fleeing as well. AIDS. 2022;36(12):1745–6.CrossRef Kai J, Parczewski M, van de Vijver D. The war refugees from Ukraine: an HIV epidemic is fleeing as well. AIDS. 2022;36(12):1745–6.CrossRef
76.
go back to reference Kazatchkine M. Ukrainian war: an economic crisis in Eastern Europe and Central Asia will lead to a health crisis. BMJ. 2022;24(376): o793.CrossRef Kazatchkine M. Ukrainian war: an economic crisis in Eastern Europe and Central Asia will lead to a health crisis. BMJ. 2022;24(376): o793.CrossRef
Metadata
Title
Injection Drug Use and Sexual Risk Behaviors Among People who Inject Drugs in Ukraine: A Random-Intercept Latent Transition Analysis
Authors
John Mark Wiginton
Robert Booth
Lisa A. Eaton
Laramie R. Smith
Cristina Espinosa da Silva
Thomas L. Patterson
Eileen V. Pitpitan
Publication date
16-03-2023
Publisher
Springer US
Published in
AIDS and Behavior / Issue 9/2023
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-023-04024-0

Other articles of this Issue 9/2023

AIDS and Behavior 9/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.